Apr. 28 at 3:12 PM
Jupiter Neurosciences, Inc. (NASDAQ:
$JUNS ) Founder, Chairman and CEO Christer Rosén recently presented at the Second Annual Centri Capital Conference at Nasdaq MarketSite, hosted by Centri Business Consulting. In this clip, he walks investors through the structure of the company's lead clinical program.
Jupiter Neurosciences is a B2i Digital Featured Company (https://b2idigital.com/jupiter-neurosciences-1) developing therapies and consumer wellness products built on its proprietary JOTROL micellar resveratrol delivery platform. For more information, visit https://www.jupiterneurosciences.com and follow Jupiter on LinkedIn.
Watch the clip here: https://youtube.com/shorts/RQwFxk1MlZg
"It's led by Professor Charbel Moussa at Georgetown as the lead PI, and he has two MedStar centers that is also doing this with the best PIs you can have in Parkinson's because they believe that it's going to work. Relatively short study, 30 patients," Rosen explained, describing the trial design and the lead investigator's commitment to the program.
A few design choices stand out in the Phase 2a protocol:
• Primary endpoints are anchored in safety and pharmacokinetics, which Jupiter has already demonstrated in Phase 1. Secondary endpoints cover motor function, fall rates, and biomarkers including IL-6, neurofilament light, and TREM-2.
• The 30-patient, placebo-controlled design is deliberately compact, supporting a shorter enrollment period and a top-line readout timed for the end of 2026.
• The 200 mg and 400 mg arms sit well below the GI side effect threshold of approximately 1.5 to 2 grams per day associated with standard resveratrol. Jupiter's 9x bioavailability means therapeutic effect at a fraction of the dose.
• A successful readout opens the door to strategic partnership discussions or NIA grant funding for follow-on indications such as Alzheimer's and mild cognitive impairment.
Watch the full presentation, courtesy of Centri Business Consulting: https://youtu.be/nN6XL3_Q8aI
Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison Silva, President and Chief Business Officer; Saleem Elmasri, CPA, Chief Financial Officer; and Marsh Hayward, Ph.D., Co-Founder and Chief Scientific Officer.
For additional details, please visit the investor section of Jupiter's website at: https://jupiterneurosciences.com/investors/. For investor inquiries, contact
[email protected].
Content shared here is for general information only and is not an offer to buy or sell any security. Any securities-related activities by our personnel are conducted solely through an appropriately registered broker-dealer, separate from services provided by B2i Digital.
$INMB,
$ANVS,
$AVXL,
$ATHA,
$XBI